Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


New Healthcare AI Partnership Aims to Transform Health Risk Assessments

View Important Disclosures for this Article
Share on Stocktwits

Source: AI Inc. has entered into a collaborative agreement with Health Care Services International Inc. to leverage its advanced healthcare AI engine and enhance services. Read on to learn what this means for the growing sector. AI Inc. (TRUE:CSE; TREIF:OTCMKTS;939:FRA) has entered into a Collaborative Agreement with Health Care Services International Inc., operating as Novus Health, to integrate its proprietary Global Library of Medicine (GLM) into Novus Health's Health Risk Assessment programs.

This partnership aims to leverage AI's advanced healthcare AI engine, developed with input from hundreds of global healthcare experts, to enhance the services provided by Novus Health, a leader in health navigation, supporting over 1.5 million members. The collaboration will focus on the development and testing of new tools and solutions that could improve healthcare efficiency and patient outcomes.

AI In Healthcare: A Sector In High Demand

In June 2019, The National Center of Biomechanical Medicine spoke about AI's future in healthcare. The report listed in the National Library of Medicine stated, "We believe that AI has an important role to play in the healthcare offerings of the future. In the form of machine learning, it is the primary capability behind the development of precision medicine, widely agreed to be a sorely needed advance in care."

Four years later, AI's place is ramping up quickly. In an August 24 report for Yahoo! Finance, Nvidia founder & CEO Jensen Huang was quoted as saying, "Demand for our data center platform for AI is tremendous and broad-based across industries and customers." 

Huang added, "Our demand visibility extends into next year. Our supply over the next several quarters will continue to ramp as we lower cycle times and work with our supply partners to add capacity."


The partnership between AI Inc. and Novus Health represents a significant catalyst in the expansion and enhancement of health risk assessment programs through advanced AI technologies. According to the company, this collaboration aims to incorporate's proprietary Global Library of Medicine into Novus Health's offerings, which is expected to transform the way health risks are assessed and managed for over 1.5 million members.

Dr. Essam Hamza, CEO of Treatment, noted the potential immediate impact of their AI diagnostic tools on Novus Health's customer base. "We are very excited to partner with a recognized leading healthcare firm in Novus Health. There is a near-term opportunity to implement our proprietary AI diagnostic tools into the solutions offered to their vast customer base. However, with this collaboration, we also have an opportunity to extend into new mutually developed tools and solutions that have the ability to further improve health care efficiency and patient outcomes."

Similarly, Jamie Marcellus, CEO of Novus Health, expressed enthusiasm for the integration of's AI capabilities into their services. "We are excited about the potential for's AI to augment our services. Their platform offers the possibility of unparalleled efficiency and accuracy in health risk assessments, drawing insights from vast data sets to detect patterns and predict potential risks. By leveraging these tools, our members can make better-informed decisions swiftly, enhancing care and enabling proactive interventions to mitigate health threats effectively."

This collaboration not only aims to enhance existing health risk assessment programs but also to develop and test new joint commercial applications and solutions, reflecting a strategic push to influence the health insurance market significantly. The partnership thus stands as a mutual endeavor to improve healthcare delivery and patient outcomes through innovative AI-driven tools and assessments.

Expert Analysis: The Rise of AI 

On April 22, Technical Analyst Clive Maund highlighted the upward trajectory of Treatment this year, writing, " AI has done very well since it was recommended for purchase two months ago, rising by approximately 60%. In this update, we will see why its new bull market looks set not just to continue but to accelerate with the real possibility of spectacular gains ahead."

Maund pointed out that the upswing has been going on much longer by explaining that the "AI healthcare market, valued at US$11 billion in 2021, is projected to be worth US$187 billion in 2030."

streetwise book logoStreetwise Ownership Overview* AI Inc. (TRUE:CSE; TREIF:OTCMKTS)

*Share Structure as of 4/9/2024

He summed up his feelings about the stock's long-term appeal by writing, "The conclusion is that this is an exceptionally bullish setup, both fundamentally and technically. So we stay long, and Treatment AI is rated as a Strong Buy here for all timeframes." 

Ownership and Share Structure

According to Reuters, two insiders own 13.12%, or 4.87 million (4.87M) shares, of AI. They are Chief Medical Officer, Chairman, and Director Dr. Kevin Peterson, with 10.35% or 3.84M shares.

Retail investors own the remaining 86.88%. There are no institutional investors currently. 

The company has 39,243,518  million outstanding shares and 25,940,377 free-float traded shares. 

Its market cap is CA$24,330,981, and its 52-week trading range is CA$0.10 to CA$1.20 per share. 

Want to be the first to know about interesting Healthcare Services investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. Subscribe

Important Disclosures:

  1. AI Inc. has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000.
  2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of AI Inc.
  3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
  4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 

For additional disclosures, please click here.

Contributing Author Disclosures

  1. Author Certification and Compensation: [Clive Maund of] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing this article. Maund received his UK Technical Analysts’ Diploma in 1989.  The recommendations and opinions expressed in this content accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed. Disclosures

The above represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be  only be construed as a recommendation or solicitation to buy and sell securities.

Want to read more about Healthcare Services investment ideas?
Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe